← Leaderboards
Felix Yi-Chung Feng
University Of California, San Francisco
$6,764,664
Attributed
$12,620,102
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,824,260 · 8
By mechanism
R01$11,710,877 · 4
P50$2,400,956 · 2
P01$529,166 · 1
P30$183,261 · 1
Top collaborators
- Paul L Nguyen8 shared
- Alan Ashworth6 shared
- Thomas Hope5 shared
- Nupam P Mahajan5 shared
- Eric J Small1 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Renuka Sriram$2,377,614
- Thomas Hope$3,566,163
- Alan Ashworth$14,084,307
- Rahul Aggarwal$5,953,056
- Susan Halabi$7,630,539
Others in their field
Other Emerging Leaders on “Sampling”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$181,167,581
- Beth Baseler · Leidos Biomedical Research, Inc.$105,136,677
- Scott Topper · Broad Institute, Inc.$77,958,806
- Paul F Gallagher · Woods Hole Oceanographic Institution$63,916,876
- Leonard Freedman · Leidos Biomedical Research, Inc.$60,323,945
- Dale Sandler · Social And Scientific Systems, Inc.$59,740,435
Research focus
SamplingGenomicsResponseBiological MarkersTumorBasePredicting ResponseMolecularCancer PatientTreatment ResponseMalignant Neoplasm Of ProstateCell LineFutureAndrogen Deprivation TherapyCastration Resistant Prostate CancerMalignant NeoplasmsPersonalized MedicineBioinformaticsPublishingTissuesEventHigh RiskPhase Iii TrialCessation Of Life
Grant awards (28)
Molecular Drivers and Therapeutic Susceptibilities in Neuroendocrine Prostate Cancer$529,166
P01 · FY2025 · CA · contact PI
UCSF Specialized Programs of Research Excellence (SPOREs) in Prostate Cancer$2,204,158
P50 · FY2024 · CA
Biomarker Approaches to Individualizing Systemic Therapy for High Risk Prostate Cancer$625,840
R01 · FY2024 · CA · contact PI
MELT: Modulation of PSMA Expression for Lutetium Therapy$618,546
R01 · FY2024 · CA
Administrative Core$196,798
P50 · FY2024 · CA · contact PI
Prostate Cancer Program$183,261
P30 · FY2024 · CA · contact PI
Biomarker Approaches to Individualizing Systemic Therapy for High Risk Prostate Cancer$655,198
R01 · FY2023 · CA · contact PI
Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic Strategies$651,939
R01 · FY2023 · CA
MELT: Modulation of PSMA Expression for Lutetium Therapy$638,248
R01 · FY2022 · CA
Biomarker Approaches to Individualizing Systemic Therapy for High Risk Prostate Cancer$620,906
R01 · FY2022 · CA · contact PI
Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic Strategies$598,615
R01 · FY2022 · CA
DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications$509,544
R01 · FY2022 · CA
Biomarker Approaches to Individualizing Systemic Therapy for High Risk Prostate Cancer$54,292
R01 · FY2022 · CA · contact PI
MELT: Modulation of PSMA Expression for Lutetium Therapy$651,214
R01 · FY2021 · CA
Biomarker Approaches to Individualizing Systemic Therapy for High Risk Prostate Cancer$633,505
R01 · FY2021 · CA · contact PI
Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic Strategies$533,911
R01 · FY2021 · CA
DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications$529,020
R01 · FY2021 · CA
Biomarker Approaches to Individualizing Systemic Therapy for High Risk Prostate Cancer$110,397
R01 · FY2021 · CA · contact PI
Biomarker Approaches to Individualizing Systemic Therapy for High Risk Prostate Cancer$71,828
R01 · FY2021 · CA · contact PI
Biomarker Approaches to Individualizing Systemic Therapy for High Risk Prostate Cancer$651,833
R01 · FY2020 · CA · contact PI
DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications$537,593
R01 · FY2020 · CA
Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic Strategies$505,524
R01 · FY2020 · CA
MELT: Modulation of PSMA Expression for Lutetium Therapy$195,347
R01 · FY2020 · CA
MELT: Modulation of PSMA Expression for Lutetium Therapy$647,080
R01 · FY2019 · CA
DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications$526,795
R01 · FY2019 · CA
Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic Strategies$523,797
R01 · FY2019 · CA
DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications$55,250
R01 · FY2019 · CA
DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications$564,655
R01 · FY2018 · CA